Register
Journal Updates
eMediNexus Coverage from: 
A new antibiotic for pneumonia and skin infections
eMediNexus,  04 October 2018
remove_red_eye 782 Views
#Dermatology #Emergency Medicine #Pharmacist #Pulmonary Medicine

1 Read Comments                

The FDA approved omadacycline (Nuzyra) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a semisynthetic derivative tetracycline antibiotic, specifically designed to overcome tetracycline resistance and proven to be effective across Gram-positive, Gram-negative, and other drug-resistant strains.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now